High-Risk Medications in Persons Living With Dementia: A Randomized Clinical Trial.

Importance

Individuals with Alzheimer disease (AD) and Alzheimer disease-related dementias (ADRD) may be at increased risk for adverse outcomes relating to inappropriate prescribing of certain high-risk medications, including antipsychotics, sedative-hypnotics, and strong anticholinergic agents.

Objective

To evaluate the effect of a patient/caregiver and prescriber-mailed educational intervention on potentially inappropriate prescribing to patients with AD or ADRD.

Design, setting, and participants

This prospective, open-label, pragmatic randomized clinical trial, embedded in 2 large national health plans, was conducted from April 2022 to June 2023. The trial included patients with AD or ADRD and use of any of 3 drug classes targeted for deprescribing (antipsychotics, sedative-hypnotics, or strong anticholinergics).

Interventions

Patients were randomized to 1 of 3 arms: (1) a mailing of educational materials specific to the medication targeted for deprescribing to both the patient and their prescribing clinician; (2) a mailing to the prescribing clinician only; or (3) a usual care arm.

Main outcomes and measures

Analysis was performed using a modified intention-to-treat approach. The primary study outcome was the dispensing of the medication targeted for deprescribing during a 6-month study observation period. Secondary outcomes included changes in medication-specific mean daily dose and health service utilization.

Results

Among 12 787 patients included in the modified intention-to-treat analysis, 8742 (68.4%) were female, and the mean (SD) age was 77.3 (9.4) years. The cumulative incidence of being dispensed a medication targeted for deprescribing was 76.7% (95% CI, 75.4-78.0) in the patient and prescriber mailing group, 77.9% (95% CI, 76.5-79.1) in the prescriber mailing only group, and 77.5% (95% CI, 76.2-78.8) in the usual care group. Hazard ratios were 0.99 (95% CI, 0.94-1.04) for the patient and prescriber group and 1.00 (95% CI, 0.96-1.06) for the prescriber only group compared with the usual care group. There were no differences between the groups for secondary outcomes.

Conclusions and relevance

These findings suggest medication-specific educational mailings targeting patients with AD or ADRD and their clinicians are not effective in reducing the use of high-risk medications.

Trial registration

ClinicalTrials.gov Identifier: NCT05147428.

CommentOn

JAMA Intern Med. 2024 Dec 1;184(12):1433-1435. doi: 10.1001/jamainternmed.2024.5642

References:

• Hukins D, Macleod U, Boland JW. Identifying potentially inappropriate prescribing in older people with dementia: a systematic review. Eur J Clin Pharmacol. 2019;75(4):467-481. doi:10.1007/s00228-018-02612-x
• Singh S, Cocoros NM, Li X, et al. . Developing a Program to Educate and Sensitize Caregivers to Reduce the Inappropriate Prescription Burden in the Elderly With Alzheimer’s Disease (D-PRESCRIBE-AD): trial protocol and rationale of an open-label pragmatic, prospective randomized controlled trial. PLoS One. 2024;19(2):e0297562. doi:10.1371/journal.pone.0297562
• Cocoros NM, Gurwitz JH, Cziraky MJ, et al. . Pragmatic guidance for embedding pragmatic clinical trials in health plans: large simple trials aren’t so simple. Clin Trials. 2023;20(4):416-424. doi:10.1177/17407745231160459
• Platt R, Brown JS, Robb M, et al. . The FDA Sentinel Initiative—an evolving national resource. N Engl J Med. 2018;379(22):2091-2093. doi:10.1056/NEJMp1809643
• Pokorney SD, Cocoros N, Al-Khalidi HR, et al. . Effect of mailing educational material to patients with atrial fibrillation and their clinicians on use of oral anticoagulants: a randomized clinical trial. JAMA Netw Open. 2022;5(5):e2214321. doi:10.1001/jamanetworkopen.2022.14321